G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
Stock Information for Black Diamond Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.